| Literature DB >> 33485651 |
Julia Borowczyk1, Maria Shutova1, Nicolo Costantino Brembilla1, Wolf-Henning Boehncke2.
Abstract
IL-25, also known as IL-17E, is a unique cytokine of the IL-17 family. Indeed, IL-25 exclusively was shown to strongly induce expression of the cytokines associated with type 2 immunity. Although produced by several types of immune cells, such as T cells, dendritic cells, or group 2 innate lymphoid cells, a vast amount of IL-25 derives from epithelial cells. The functions of IL-25 have been actively studied in the context of physiology and pathology of various organs including skin, airways and lungs, gastrointestinal tract, and thymus. Accumulating evidence suggests that IL-25 is a "barrier surface" cytokine whose expression depends on extrinsic environmental factors and when upregulated may lead to inflammatory disorders such as atopic dermatitis, psoriasis, or asthma. This review summarizes the progress of the recent years regarding the effects of IL-25 on the regulation of immune response and the balance between its homeostatic and pathogenic role in various epithelia. We revisit IL-25's general and tissue-specific mechanisms of action, mediated signaling pathways, and transcription factors activated in immune and resident cells. Finally, we discuss perspectives of the IL-25-based therapies for inflammatory disorders and compare them with the mainstream ones that target IL-17A.Entities:
Keywords: Crohn disease; IL-17E; IL-25; asthma; atopic dermatitis; chronic rhinosinusitis; contact dermatitis; epithelial cells; idiopathic pulmonary fibrosis; inflammatory bowel disease; keratinocytes; psoriasis; tuft cells; ulcerative colitis
Year: 2021 PMID: 33485651 DOI: 10.1016/j.jaci.2020.12.628
Source DB: PubMed Journal: J Allergy Clin Immunol ISSN: 0091-6749 Impact factor: 10.793